Scientists have developed a rapid, highly accurate test to detect antibodies against the spike protein of SARS-CoV-2 in human serum, opening a new avenue for understanding the full extent of the pandemic and evaluating the effectiveness of vaccines.

In the 18 months since the emergence of COVID-19 pandemic, great strides have been made in discovering and inventing various approaches to track and control the spread of the SARS-CoV-2 virus. The gold standard since the beginning of the pandemic has been the RT-PCR method.

A team of scientists from Japan, including Prof. Manabu Tokeshi of Hokkaido University’s faculty of engineering, have developed a 20-minute test to detect and quantify antibodies against SARS-CoV-2 in human serum. Their findings were published in Biosensors and Bioelectronics.1

It is estimated that between 40 and 45 percent of individuals infected with SARS-CoV-2 are asymptomatic — despite being infected, they do not develop any symptoms of the disease. Identifying individuals who may have had asymptomatic COVID-19 is important to understanding the full extent of the pandemic. RT-PCR can only detect the presence of the viral RNA in samples; individuals who have recovered from the pandemic will only have antibodies to the virus, which RT-PCR cannot detect.

They developed a method of detecting antibodies against SARS-CoV-2 in human serum using a method called non-competitive fluorescence polarization immunoassay (FPIA). This method can also be used to quantify the antibodies. The team has previously made many innovations to the method and associated equipment, including the development of a portable fluorescence polarization analyzer (see Figure 1).

FPIA requires fluorescently labeled recombinant SARS-CoV-2 spike proteins (F-RBD) and human serum to be mixed together for the test. Individuals who have been infected with or vaccinated against SARS-CoV-2 will have anti-spike protein antibodies in their serum. When these antibodies bind to F-RBD, polarized light is emitted, while F-RBD alone emits depolarized light. By measuring the degree of polarization using a fluorescence polarization analyzer, the concentration of antibodies can be determined. The scientists optimized the test and evaluated it using samples of human serum from individuals diagnosed with COVID-19 and from those who had not been infected by SARS-CoV-2 (see Figure 2).

Fig. 2 - The principle behind FPIA for detection of antibodies against SARS-CoV-2. When free fluorescently labeled recombinant SARS-CoV-2 spike proteins (F-RBD) are exposed to a specific wavelength of polarized light, they emit depolarized light. However, if F-RBD are bound to anti-RBD antibodies, they emit polarized light instead, which can be measured.

The test was demonstrated to be highly accurate, quick, and easy to perform, with high throughput. This test requires about 20 minutes to complete, compared to about 2 hours for other tests; furthermore, the equipment required for the test is highly portable, weighing only 4.3 kg. Taken all together, these features make the test an excellent option for detecting and quantifying antibodies against SARS-CoV-2. The test can now be used for two purposes: screening large populations to determine the exact extent of the pandemic, and for evaluating the effectiveness of SARS-CoV-2 vaccines based on the antibody response.

This work was supported by the Japan Science and Technology Agency’s JST-SENTAN program (JPMJSN16A2); the Nakatani Foundation for Advancement of Measuring Technologies in Biomedical Engineering; the Japan Society for the Promotion of Science (JSPS) KAKENHI (JP20H02760), and Grant-in-Aid for JSPS Fellows (20J11226); and the Cooperative Research Program of the Network Joint Research Center for Materials and Devices (NJRC Mat. & Dev.).

Reference

  1. Keine Nishiyama, et al., “Facile and rapid detection of SARS-CoV-2 antibody based on a noncompetitive fluorescence polarization immunoassay in human serum samples,” Biosensors and Bioelectronics, June 5, 2021, DOI: 10.1016/j.bios.2021.113414.

For more information, visit here .


Medical Design Briefs Magazine

This article first appeared in the September, 2021 issue of Medical Design Briefs Magazine.

Read more articles from this issue here.

Read more articles from the archives here.